Introduction Emzumab, a brand of Omalizumab, is a monoclonal antibody that effectively treats severe allergic asthma, nasal polyps, and chronic idiopathic urticaria (CIU). Developed by Cipla, Emzumab is essential for patients needing advanced therapeutic options.
Omalizumab for asthma therapy:
- Asthma Management: Suitable for patients aged 6 and older with severe persistent asthma not controlled by inhaled corticosteroids.
- Nasal Polyps: Reduces polyp size and improves nasal airflow for adults needing additional treatment beyond corticosteroids.
- CIU Relief: Alleviates symptoms for patients aged 12 and older unresponsive to antihistamines.
Dosage and Administration: Emzumab is administered subcutaneously, with dosages ranging from 75 mg to 600 mg every 2-4 weeks based on the condition, weight, and IgE levels.
Safety and Precautions
- Not for acute asthma attacks.
- Monitor for hypersensitivity reactions.
- Gradual reduction of corticosteroids under medical supervision is advised.
Global Export Services: We export Emzumab in bulk, adhering to high-quality standards and ensuring global accessibility. Competitive pricing and reliable shipping options are available for bulk purchases.
Buying Information: For those interested in the Omalizumab injection price in India or looking to buy Omalizumab 150mg injections, our platform offers competitive pricing and quality assurance. You can buy Emzumab injection directly from India through our streamlined process.
Conclusion:
Emzumab (Omalizumab) is a vital medication for managing severe asthma, nasal polyps, and CIU. For bulk purchases and more information, visit Indian Generic Medicines (www.indiangenericmedicines.com).
